Menu

Expected Retraction Published

The repeal of a Molecular Endocrinology paper is the second of three anticipated retractions from a cell biologist.

Jan 13, 2016
Kerry Grens

WIKIMEDIA, LILLY_MMolecular Endocrinology has retracted a paper from Sudarsanareddy Lokireddy, a former cell biology researcher at Nanyang Technological University in Singapore whose work has been flagged by the university for figure tampering. Already, Lokireddy—who is now listed as a postdoc at Harvard Medical School—was blamed for one retraction, and Retraction Watch previously reported that another is still to come.

The latest retraction concerns a study about the role of myostatin in skeletal muscle wasting. According to the retraction notice, “a substantial number of falsifications of Western blot data by the first author [Lokireddy] have been established (Figures 2C, 3C, and 6C).”

An investigation led by Nanyang Technological University concluded that several of Lokireddy and colleagues’ papers contained data that were improperly altered. “All authors have agreed, except for Sudarsanareddy Lokireddy,” according to the university’s report.

Lokireddy’s first retraction was of a 2012 Cell Metabolism study that also examined a protein involved in skeletal muscle wasting. Retraction Watch reported last month (December 15) that a retraction in Biochemical Journal of a third paper by Lokireddy is imminent; the publication has already issued a correction on the article.

Update (February 2): Molecular Endocrinology published an extensive correction of a 2014 paper by Lokireddy and colleagues on Monday (February 1). According to the Corrigendum, figures 2, 3, 4, 5, and 6 all contained errors related to data "presented without proper explanation of how they were derived." In many instances, it appears that blots were copy-and-pasted in the figures, the journal noted. The correction does not explain whether the conclusions of the study were compromised.

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.